Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Bluejay Diagnostics, Inc.BJDX · Entity 8627 | Director | August 17, 2026 | August 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Bluejay Diagnostics, Inc.
Report date August 17, 2026 · Filed August 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.08 · Expires 2031-08-17 | Direct | 100,000 |
Reported balance
After 2026-08-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-08-17 · Grant · Acquired 100,000 · Balance 100,000 F1: Represents out-of-the-money stock options that vest and become exercisable for $2.075 per share on the first anniversary of the grant date, provided, however, that the options shall not be exercisable unless and until the U.S. Food and Drug Administration shall have granted clearance or approval of the issuer's Symphony IL-6 point-of-care testing device. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents out-of-the-money stock options that vest and become exercisable for $2.075 per share on the first anniversary of the grant date, provided, however, that the options shall not be exercisable unless and until the U.S. Food and Drug Administration shall have granted clearance or approval of the issuer's Symphony IL-6 point-of-care testing device.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 17, 2026 Filed Aug 18, 2026 20:15 UTC | Bluejay Diagnostics, Inc. BJDX · Entity 8627 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $2.08 | $0.00 |
DisclosureSEC source: 0001123292-26-001125 · form4.xml · derivative · entry 1 Dey Svetlana · CIK 0001889314 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2031-08-17 F1 · derivative.exercise_date: Represents out-of-the-money stock options that vest and become exercisable for $2.075 per share on the first anniversary of the grant date, provided, however, that the options shall not be exercisable unless and until the U.S. Food and Drug Administration shall have granted clearance or approval of the issuer's Symphony IL-6 point-of-care testing device. Read SEC document |
| March 14, 2026 Filed May 18, 2026 21:18 UTC | Bluejay Diagnostics, Inc. BJDX · Entity 8627 | PurchaseCommon Stock | 12,500 | $2.00 | $25,000.00 |
DisclosureSEC source: 0001123292-26-000686 · form4.xml · nonDerivative · entry 1 Dey Svetlana · CIK 0001889314 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,501 F1 · shares: On March 14, 2026, Ms. Dey purchased 12,500 shares of the issuer's common stock from the issuer in a private placement at a price of $2.00 per share. Read SEC document |
| December 13, 2023 Filed Dec 14, 2023 21:17 UTC | Bluejay Diagnostics, Inc. BJDX · Entity 8627 | PurchaseCommon Stock | 500 | $3.07 | $1,535.00 |
DisclosureSEC source: 0001062993-23-022569 · form4.xml · nonDerivative · entry 1 Dey Svetlana · CIK 0001889314 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,500 Read SEC document |
| March 24, 2023 Filed Mar 24, 2023 17:48 UTC | Bluejay Diagnostics, Inc. BJDX · Entity 8627 | GrantCommon Stock | 10,000 | $0.44 | $4,400.00 |
DisclosureSEC source: 0001213900-23-022724 · ownership.xml · nonDerivative · entry 1 Dey Svetlana · CIK 0001889314 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,500 Read SEC document |
| March 24, 2023 Filed Mar 31, 2023 17:46 UTC Amendment | Bluejay Diagnostics, Inc. BJDX · Entity 8627 | PurchaseCommon Stock | 10,000 | $0.44 | $4,400.00 |
DisclosureSEC source: 0001213900-23-025245 · ownership.xml · nonDerivative · entry 1 Dey Svetlana · CIK 0001889314 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,500 F2 · kind: The original Form 4, filed on March 24, 2023 is being amended by this Form 4 amendment solely to correct an administrative error which misreported this transaction as a grant with a transaction code of "A" instead of an open market purchase with a transaction code of "P." Read SEC document |
| February 01, 2023 Filed Feb 13, 2023 22:41 UTC | Bluejay Diagnostics, Inc. BJDX · Entity 8627 | GrantCommon Stock | 27,500 | $0.44 | $12,100.00 |
DisclosureSEC source: 0001213900-23-010887 · ownership.xml · nonDerivative · entry 1 Dey Svetlana · CIK 0001889314 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,500 Read SEC document |
| March 22, 2022 Filed Mar 23, 2022 22:13 UTC | Bluejay Diagnostics, Inc. BJDX · Entity 8627 | GrantOption to purchase common stock · Derivative | 2,500 | Not disclosed Strike: $1.26 | Not disclosed |
DisclosureSEC source: 0001213900-22-014580 · ownership.xml · derivative · entry 1 Dey Svetlana · CIK 0001889314 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,500 Underlying: Common Stock · 2,500 shares Expires 2032-03-22 F2 · price: The stock options were issued in connection with the reporting person's Board of Director services to the Company. F1 · derivative.exercise_date: The stock options set forth in this table vest on December 15, 2022, subject to the grantee's continued service to the Company on the vesting date. Read SEC document |
| March 17, 2022 Filed Mar 21, 2022 13:31 UTC | Bluejay Diagnostics, Inc. BJDX · Entity 8627 | PurchaseCommon Stock | 10,000 | $1.18 | $11,830.00 |
DisclosureSEC source: 0001213900-22-013761 · ownership.xml · nonDerivative · entry 1 Dey Svetlana · CIK 0001889314 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 F1 · price: This transaction was executed in multiple trades at prices ranging from $1.17 to $1.19. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · balance_after: Does not include 4,091,356 shares held by Lana Management & Business Research International, LLC, an entity owned by Mr. Indranil Dey and Ms. Svetlana Dey. Ms. Dey has voting and dispositive power over the shares held by such entity. Read SEC document |
| January 10, 2022 Filed Jan 14, 2022 00:31 UTC | Bluejay Diagnostics, Inc. BJDX · Entity 8627 | GrantOption to purchase common stock · Derivative | 25,000 | Not disclosed Strike: $2.79 | Not disclosed |
DisclosureSEC source: 0001213900-22-002007 · ownership.xml · derivative · entry 1 Dey Svetlana · CIK 0001889314 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2032-01-10 F2 · price: The stock options were issued in connection with the reporting person's Board of Director services to the Company. F1 · derivative.exercise_date: The stock options set forth in this table vest on December 15, 2022, subject to the grantee's continued service to the Company on the vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.